Associated Banc Corp Buys 87 Shares of Johnson & Johnson (NYSE:JNJ)

Associated Banc Corp increased its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 178,524 shares of the company’s stock after acquiring an additional 87 shares during the period. Johnson & Johnson comprises approximately 1.4% of Associated Banc Corp’s investment portfolio, making the stock its 16th largest holding. Associated Banc Corp’s holdings in Johnson & Johnson were worth $31,689,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. Vanguard Group Inc. increased its position in Johnson & Johnson by 1.4% during the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after buying an additional 3,358,478 shares during the last quarter. GQG Partners LLC increased its position in Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after buying an additional 2,547,378 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after buying an additional 1,805,632 shares during the last quarter. Swiss National Bank increased its position in Johnson & Johnson by 14.0% during the first quarter. Swiss National Bank now owns 11,402,516 shares of the company’s stock worth $2,020,868,000 after buying an additional 1,396,500 shares during the last quarter. Finally, Bridgewater Associates LP increased its position in Johnson & Johnson by 40.3% during the first quarter. Bridgewater Associates LP now owns 4,345,002 shares of the company’s stock worth $770,065,000 after buying an additional 1,247,260 shares during the last quarter. Institutional investors own 68.59% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,707,775. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,707,775. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 16,410 shares of the company’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total value of $2,845,822.20. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The disclosure for this sale can be found here. Insiders sold 135,723 shares of company stock worth $23,192,574 over the last three months. Insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on JNJ shares. Raymond James lowered their price target on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Atlantic Securities decreased their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Credit Suisse Group initiated coverage on Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price on the stock. Sanford C. Bernstein decreased their target price on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Finally, Citigroup decreased their target price on Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Seven equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Trading Up 0.5 %

Shares of JNJ stock opened at $175.97 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The stock has a market cap of $460.07 billion, a P/E ratio of 24.51, a price-to-earnings-growth ratio of 3.49 and a beta of 0.57. The stock has a 50 day simple moving average of $168.04 and a 200 day simple moving average of $171.28. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.49 by $0.06. The business had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.60 earnings per share. On average, research analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson declared that its Board of Directors has approved a share buyback plan on Wednesday, September 14th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the company to purchase up to 1.2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.57%. The ex-dividend date of this dividend is Monday, November 21st. Johnson & Johnson’s payout ratio is presently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.